Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Using Model-based Meta-analysis to Inform Drug Development for Autoimmune Diseases

MBMA helps sponsors design less costly and more precise trials with an eye toward achieving commercial success for both the drug and portfolio. Watch this webinar with Dr. Mark Lovern, Vice President at Certara Strategic Consulting, to learn how leveraging public data can provide value by abbreviating the “cash spiral” inherent to proprietary data.

Speaker(s): Mark Lovern
Solution: Model-based Meta-analysis, PK/PD Modeling & Simulation
More Info

How to Perform Level C IVIVC in Phoenix

In this webinar, Professor Jean-Michel Cardot explained how to perform Level C IVIVC using Phoenix. Learn how to calculate pharmacokinetic parameters via the non-compartmental analysis module; how to calculate dissolution parameters via the dissolution module; how to link the in vivo pharmacokinetic parameters and in vitro dissolution parameters via the linear relationship module; and how to calculate dissolution limits.

Speaker(s): Jean-Michel Cardot
Solution: PK/PD Modeling & Simulation
More Info

What’s New in the Simcyp Simulator v17?

Watch this webinar with Nikunjkumar Patel, Oliver Hatley, and Matthew Harwood to learn how the latest updates in the Simcyp Simulator v17 will help provide insights that support developing safer, more effective medications.

Speaker(s): Nikunjkumar Patel, Matthew Harwood, Oliver Hatley
Solution: PBPK Modeling & Simulation
Therapeutic Area: Oncology/Hematology
More Info

Best Practices in Clinical Pharmacology Gap Analysis

Watch this webinar to learn from Dr. Julie Bullock, Senior Director of Consulting Services at Certara, how gap analysis can help you ensure that your development program will contain all the elements needed to satisfy regulators and investors during all phases of drug development from IND to NDA.

Speaker(s): Julie Bullock
Solution: Clinical Pharmacology Strategy
More Info

How Can You Get the Most out of Phoenix 8.0?

In this webinar, Dr. Nathan Teuscher demonstrated how to get the most out of Phoenix 8.0’s new features, including how to automatically calculate new NCA parameters, set up parallelization of Phoenix NLME runs, and leverage the new validation suite to get up and running in no time.

Speaker(s): Nathan Teuscher
Solution: PK/PD Modeling & Simulation
More Info

Using PBPK Models to Optimize Anti-HIV Drug Dosing for Pregnant Women

In this webinar, we will discussed how we combined clinical and pre-clinical approaches to develop a PBPK model to predict the exposure of darunavir, a protease inhibitor commonly used to treat pregnant HIV+ patients. Moreover, we elaborated on the study design, data collection, and analyses that were used to investigate the clinical pharmacokinetics of antiretroviral agents during pregnancy.

Speaker(s): Angela Colbers, Rick Greupink
Solution: PBPK Modeling & Simulation
Therapeutic Area: Infectious Disease
More Info

Emerging Issues for Pharma R&D: A Practical Approach for Pediatric Drug Programs

In this webinar, Dr. Barry Mangum from Paidion Research and Dr. JF Marier from Certara discussed how pediatric considerations fit into the overall drug development program. They also made recommendations for addressing issues from both a practical and scientific perspective. Anonymized case studies were presented with a review of historical issues with a focus on solutions for today (ie, licensed comparators differences in US and EU, importation issues, and endpoint selection).

Speaker(s): Jean-Francois Marier, Barry Mangum
Solution: Drug Development & Regulatory Strategy
Therapeutic Area: Pediatrics
More Info

Using Model Reduction to Bridge the QSP-Pharmacometrics Divide

In this webinar, Dr. Tom Snowden demonstrated: why reduction methods are a potent and necessary tool in the modeler’s arsenal; how reduction methods can be applied to QSP models; and, how model reduction can be used to extract scientific and business insights from complex models.

Speaker(s): Tom Snowden
Solution: PBPK Modeling & Simulation, PK/PD Modeling & Simulation, Systems Pharmacology
More Info
Learn More LinkedIn Twitter Facebook Email